Bellerophon Therapeutics, Inc. Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease
Bellerophon Therapeutics, Inc. announced top-line results from its pivotal Phase 3 REBUILD clinical trial evaluating the safety and efficacy of INOpulse® for the treatment of fibrotic Interstitial... | June 6, 2023
Bellerophon Therapeutics Inc Bellerophon Therapeutics Interstitial Lung Disease Overall Activity Walk Distance Respiratory Questionnaire
Source: marketscreener.com